N18.2

Chronic kidney disease, stage 2 (mild)

Chronic Kidney Disease (CKD) Stage 2, also referred to as mild CKD, represents a persistent reduction in kidney function characterized by a glomerular filtration rate (GFR) between 60-89 mL/min/1.73m² and evidence of kidney damage present for three months or more. While the GFR is slightly reduced from normal (which is typically 90 mL/min/1.73m² or higher), the defining aspect of CKD Stage 2 is the presence of kidney damage, such as albuminuria (protein in the urine), hematuria (blood in the urine), or structural abnormalities identified through imaging studies, even if the GFR alone might be considered within a 'normal' range for some individuals. ## Pathophysiology CKD is a progressive condition where the kidneys gradually lose their ability to filter waste products and excess fluid from the blood. In Stage 2, the underlying pathological processes leading to kidney damage are already active, even if the functional decline is still relatively subtle. These processes often involve chronic inflammation, glomerulosclerosis, tubulointerstitial fibrosis, and vascular damage. Regardless of the primary etiology (e.g., diabetes, hypertension, glomerulonephritis), the common pathway involves the loss of functional nephrons and the compensatory hypertrophy of remaining nephrons, which initially maintains GFR but eventually contributes to further damage due to hyperfiltration and increased workload. The presence of albuminuria, a key indicator of kidney damage, reflects increased permeability of the glomerular filtration barrier, often an early sign of progressive disease. ## Clinical Presentation Patients with CKD Stage 2 are often asymptomatic. The kidneys still largely maintain their homeostatic functions, and waste product accumulation is usually not significant enough to cause overt symptoms. However, subtle signs might be present, such as nocturia (frequent urination at night) due to impaired concentrating ability of the kidneys, or mild, non-specific fatigue. If the underlying cause of kidney disease (e.g., poorly controlled hypertension or diabetes) is symptomatic, those symptoms may dominate the clinical picture. Edema may be present, particularly if significant proteinuria is also occurring. Laboratory abnormalities beyond the GFR reduction might include mild anemia or slight elevations in parathyroid hormone (PTH) levels, indicating early mineral and bone disorder of CKD. ## Diagnostic Criteria Diagnosis of CKD Stage 2 requires two main components to be present for at least three months: * **GFR:** An estimated GFR (eGFR) consistently between 60 and 89 mL/min/1.73m². * **Evidence of Kidney Damage:** One or more of the following indicators of kidney damage: * Albuminuria (albumin-to-creatinine ratio (ACR) ≥ 30 mg/g, or urine albumin excretion ≥ 30 mg/24 hours). * Hematuria (persistent microscopic or macroscopic hematuria, after excluding urological causes). * Pathological abnormalities detected by renal biopsy. * Structural abnormalities on imaging (e.g., polycystic kidneys, hydronephrosis, small kidneys). * History of kidney transplantation. Routine blood tests for serum creatinine (to estimate GFR) and urine tests for albuminuria are crucial for diagnosis and monitoring. ## Standard of Care The primary goals of managing CKD Stage 2 are to identify and treat the underlying cause, slow the progression of kidney damage, and prevent complications. Key components of management include: * **Blood Pressure Control:** Aggressive control of hypertension, typically targeting below 130/80 mmHg, often with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), which also help reduce proteinuria. * **Glycemic Control:** For diabetic patients, maintaining strict glycemic control (HbA1c targets often individualized but generally around <7%) is critical. * **Proteinuria Reduction:** ACEIs or ARBs are first-line agents for reducing albuminuria, regardless of blood pressure status, given their renoprotective effects. * **Lifestyle Modifications:** Dietary modifications (low sodium, moderate protein intake), regular physical activity, weight management, and smoking cessation are essential. * **Avoidance of Nephrotoxic Agents:** Caution with NSAIDs, certain antibiotics, and contrast media. Dose adjustment for renally excreted medications may be necessary. * **Monitoring:** Regular monitoring of GFR, albuminuria, electrolytes, hemoglobin, and bone mineral markers (calcium, phosphate, PTH). * **Referral to Nephrology:** Consideration for nephrology referral, especially if there is uncertainty about the etiology, rapid progression, resistant hypertension, significant albuminuria, or other complications.

Clinical Symptoms

  • Often asymptomatic
  • Nocturia (frequent urination at night)
  • Mild fatigue
  • Subtle swelling or edema (if significant proteinuria)
  • Foamy urine (due to proteinuria)
  • Muscle cramps
  • Poor appetite (rare, but possible if uremia begins to build)

Common Causes

  • Diabetes mellitus (Type 1 and Type 2)
  • Hypertension (uncontrolled high blood pressure)
  • Glomerulonephritis (inflammation of the kidney's filtering units)
  • Polycystic kidney disease (inherited disorder causing cysts in the kidneys)
  • Other inherited kidney diseases (e.g., Alport syndrome)
  • Obstructive nephropathy (e.g., kidney stones, enlarged prostate, tumors blocking urine flow)
  • Recurrent pyelonephritis (kidney infections)
  • Vesicoureteral reflux (urine flowing backward from the bladder to the kidneys)
  • Systemic lupus erythematosus and other autoimmune diseases affecting the kidneys
  • Chronic use of certain medications (e.g., NSAIDs, lithium, certain illicit drugs)
  • Atherosclerosis affecting renal arteries (renal artery stenosis)

Documentation & Coding Tips

Document specific GFR and albuminuria values to confirm CKD stage and severity.

Example: Patient presents for follow-up of established CKD. Labs reveal eGFR 72 mL/min/1.73m^2 (CKD-EPI) and UACR 28 mg/g. Patient denies new symptoms. BP 130/80. Continue lisinopril 10mg daily for BP control and renal protection. Diagnosis: Chronic kidney disease, stage 2 (mild) (N18.2).

Billing Focus: Specific GFR and UACR values substantiate the CKD stage. Documentation of ongoing management (medication adjustment, monitoring) supports the complexity of the visit.

Clearly state the underlying etiology of CKD when known and document its chronic nature.

Example: 68-year-old male with long-standing uncontrolled hypertension, now presenting with chronic kidney disease secondary to hypertensive nephropathy. Current eGFR 75 mL/min/1.73m^2. Patient reports occasional lower extremity edema. Plan: Reinforce low-sodium diet, continue hydrochlorothiazide 25mg daily, and scheduled for repeat renal panel in 3 months. Diagnosis: Chronic kidney disease, stage 2 (mild) (N18.2) due to hypertensive nephropathy (I12.9).

Billing Focus: Linking CKD to its primary cause (e.g., hypertensive nephropathy) provides higher specificity and supports medical necessity for related services. This allows for dual coding (N18.2 with I12.9).

Describe complications or associated conditions related to CKD stage 2, even if mild.

Example: Patient with known N18.2, presents for routine follow-up. Current labs show hemoglobin 12.1 g/dL, consistent with mild anemia of chronic disease, not yet requiring intervention but will monitor. Patient denies fatigue. No evidence of hyperphosphatemia or hyperkalemia. Plan: Continue dietary counseling, monitor labs. Diagnosis: Chronic kidney disease, stage 2 (mild) (N18.2), with mild anemia (D63.1) likely secondary to CKD.

Billing Focus: Identifying and documenting even mild complications like 'anemia of chronic disease' (D63.1) supports medical complexity and justifies management strategies, even if only monitoring.

Document ongoing management plans, including medication adjustments, lifestyle modifications, and monitoring schedules.

Example: Patient with stable N18.2, eGFR 68 mL/min/1.73m^2. Has been compliant with metformin 500mg BID for Type 2 Diabetes (E11.9) and atorvastatin 20mg daily for hyperlipidemia (E78.5). Encouraged continued low-protein, low-sodium diet and daily exercise. Plan: Renal diet education, continue current medications, follow-up in 6 months with repeat GFR and UACR. Diagnosis: Chronic kidney disease, stage 2 (mild) (N18.2).

Billing Focus: Detailed documentation of management (medication review, lifestyle counseling, future plans) supports the level of service billed (e.g., E/M complexity).

Specify treatment goals and patient response to therapy.

Example: Patient with CKD stage 2, target BP <130/80. On lisinopril 10mg daily, current BP 128/78. UACR has remained stable at 35 mg/g over last 6 months. Patient tolerating medication well, no cough. Goals met. Diagnosis: Chronic kidney disease, stage 2 (mild) (N18.2).

Billing Focus: Documenting treatment goals and patient's response demonstrates active management and medical decision-making, justifying the encounter's complexity.

Avoid 'probable' or 'suspected' for chronic conditions unless explicitly ruled out. Use definitive diagnoses.

Example: A 55-year-old male with confirmed history of Type 2 Diabetes (E11.9) and hypertension (I10) for 15 years. Current eGFR 70 mL/min/1.73m^2 and UACR 45 mg/g. Patient referred to nephrology for ongoing management. Impression: Chronic kidney disease, stage 2 (mild) (N18.2).

Billing Focus: Definitive diagnosis of N18.2 ensures accurate billing for the chronic condition and related services. 'Probable' conditions are typically not coded in the outpatient setting.

Relevant CPT Codes

Related Diagnoses

Hierarchy